替吉奥联合奥沙利铂一线治疗晚期食管癌的研究  

Oxaliplatin combined with S-1 capsule as first-line therapy for advanced esophageal cancer

作　　者：周涛琪[1] 谢国明[1] 郑宏瑜[1] 陈科[1] 徐彩虹[1] 张琦[1] 

机构地区：[1]宁波大学医学院附属鄞州医院放化疗中心,315040

出　　处：《浙江医学》2015年第3期236-238,共3页Zhejiang Medical Journal

摘　　要：目的：探讨奥沙利铂（OXA）联合替吉奥胶囊一线治疗晚期食管癌的疗效及不良反应。方法将35例采用OXA联合替吉奥胶囊（SOX方案）化疗的晚期食管癌患者设为治疗组，32例行顺铂（DDP）联合氟尿嘧啶（DF方案）化疗的患者设为对照组。观察及随访两组患者的近、远期疗效及不良反应。结果治疗组及对照组的近期有效率分别为62.9%和37.5%，比较有统计学差异（P＜0.05），疾病控制率分别为85.7%和65.6%，组间比较无统计学差异（P＞0.05）。治疗组的中位生存期（12.4个月）与对照组（10.4个月）相比有统计学差异（P＜0.05），两组患者1年生存率分别为54.3%和34.4%，2年生存率分别为5.7%和0.0%，两组间均无统计学差异（χ2=2.680、2.654，均P＞0.05）。在不良反应方面，两组患者的血液学、消化道不良反应及肝功能损害比较无统计学差异（均P＞0.05），治疗组神经系统不良反应发生率高于对照组（P＜0.05）。结论 OXA联合替吉奥（SOX方案）治疗晚期食管癌疗效较为肯定，患者耐受良好。Objective To investigate the efficacy of oxaliplatin combined with S- 1 capsule （Tegafur, Gimeracil and Oteracil Potassium Capsules） as first- line therapy for patient with advanced esophageal cancer. Methods Sixty seven pa-tients with advanced esophageal cancer were treated with two different regimes：35 patients receiving SOX （oxaliplatin plus S- 1 capsule） as study group, and 32 patients receiving DF（cisplatin plus fluorouracil） as control group. The short- term, long- term ef-ficacy and adverse reactions were observed and compared between two groups. Results The short- term effective rate of study group was higher than that of control group （62.9%vs 37.5%, P〈0.05）, and there was no significant difference in disease control rate between two groups （85.7% vs 65.6%, P〉0.05）. The median survival time of study group was longer than that of control group （12.4 months vs 10.4 months, P〈0.05）. The 1- y survival rates were 54.3%and 34.4%, 2- y survival rates were 5.7%and 0.0% in two groups, respectively （χ2=2.680, 2.654, both P 〉0.05）. There were no significant differences in the toxicity of hematopoietic system, gastrointestinal system and liver（P〉0.05）;the neurotoxicity incidence of SOX regime was higher than that of DF regime （P〈0.05）. Conclusion Oxaliplatin combined with S- 1 capsule is an effective and wel- tolerated chemotherapy regime for advanced esophageal cancer.

关 键 词：食管肿瘤 化疗 奥沙利铂 替吉奥 S-1 

分 类 号：R735.1[医药卫生—肿瘤]